# Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

> **NCT05266612** · PHASE1 · RECRUITING · sponsor: **Virogin Biotech Canada Ltd** · enrollment: 12 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** VG2025
- **DRUG:** Nivolumab Injection [Opdivo]

## Key facts

- **NCT ID:** NCT05266612
- **Lead sponsor:** Virogin Biotech Canada Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-09
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266612, "Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05266612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*